ANGLE PLC raised $30M from new and existing investors to commercialize its Parsortix liquid biopsy for ovarian cancer as well as to support its filing with the US Food and Drug Administration.
Advanced Code injection
ANGLE PLC raised $30M from new and existing investors to commercialize its Parsortix liquid biopsy for ovarian cancer as well as to support its filing with the US Food and Drug Administration.